|
![]() |
|
|
Cimetidine
drug data and news
Cimetidine drug data, resources, and news articles (when available). Onconews.org provides news on cancer research. This section, which includes profiles on medicines that may or not be cancer-related is in beta form. If things run smoothly we will be releasing a new format late in the summer of 2006.
|
| Generic name | Cimetidine | ||
| Brand Names/Synonyms | Acibilin; Acinil; CIMETIDINE A/AB; Carbamazapine; Cimal; Cimetag; Cimetidine; Cimetidine Hcl; Cimetum; Dyspamet; Edalene; Eureceptor; FPF 1002; Gastromet; Peptol; Tagamet; Tagamet Hb; Tagamet Hb 200; Tametin; Tratul; Ulcedin; Ulcedine; Ulcerfen; Ulcimet; Ulcofalk; Ulcomedina; Ulcomet; Ulhys | ||
| Indication | For the treatment and the management of acid-reflux disorders (GERD), peptic ulcer disease, heartburn, and acid indigestion | ||
| Sponsored links | Description | Not Available | |
| Pharmacology | Cimetidine is a histamine H2-receptor antagonist. It reduces basal and nocturnal gastric acid secretion and a reduction in gastric volume, acidity, and amount of gastric acid released in response to stimuli including food, caffeine, insulin, betazole, or pentagastrin. It is used to treat gastrointestinal disorders such as gastric or duodenal ulcer, gastroesophageal reflux disease, and pathological hypersecretory conditions. Cimetidine inhibits many of the isoenzymes of the hepatic CYP450 enzyme system. Other actions of Cimetidine include an increase in gastric bacterial flora such as nitrate-reducing organisms. | ||
| Mechanism Of Action | Cimetidine binds to an H2-receptor located on the basolateral membrane of the gastric parietal cell, blocking histamine effects. This competitive inhibition results in reduced gastric acid secretion and a reduction in gastric volume and acidity. | ||
| Cimetidine News (When available) |
Oscient Pharmaceuticals Reports Financial Results for Fourth ... 06 Mar 2006 Common practice of prescribing H2 blockers to treat acid reflux in ... Feb 24, 2006 H 2 Blockers in Preemies Raise Necrotizing Enterocolitis Risk Feb 9, 2006 Basic Science Investigation Feb 9, 2006 H 2 Blockers in Preemies Raise Necrotizing Enterocolitis Risk 09 Feb 2006 Common Reflux Treatment Linked to Life Threatening Bowel Infection ... 09 Feb 2006 Will Cimetidine Hurt the Foal? Jan 10, 2006 FDA Accepts for Filing Oscient Pharmaceuticals' Supplemental New ... Jan 20, 2006 Reduce platelet aggregation, blood clotting, inflammation, nervous ... Jan 12, 2006 I’ma man with big breasts Jan 7, 2006 Cisplatin Nephrotoxicity Is Critically Mediated via the Human ... Dec 9, 2005 Sir James to step down as chancellor Dec 9, 2005 New Data on FACTIVE(R) Tablets and Ramoplanin Presented at the ... Dec 9, 2005 Treating nails when fungus, yeast invade Nov 8, 2005 Some ways to get rid of those bothersome warts Nov 22, 2005 Holiday Treats Present Temptations and Challenges for Children ... Nov 22, 2005 Holidays Present Challenges for Children With GERD Nov 23, 2005 Holiday Treats Present Temptations and Challenges for Children ... Nov 22, 2005 Oscient Pharmaceuticals to Present Clinical Data on FACTIVE(R) ... 31 Oct 2005 DR GARETH: IS TATTOO TOO RISKY FOR ME Oct 29, 2005 Ulcers mostly caused by bacteria, not stress Oct 24, 2005 Who ate all the prize? Oct 8, 2005 My brush with Nobelity Oct 11, 2005 Bacteria Linked To Heart Risk Oct 7, 2005 Vitamin B-12 supplements are insurance Oct 6, 2005 Off-Label Drug Use Oct 14, 2005 My brush with Nobelity 11 Oct 2005 B12 supplementation may not be necessary 11 Oct 2005 Who ate all the prize? Oct 8, 2005 Counter intelligence: Experts offer advice on using non ... Sep 27, 2005 Bacteria Linked To Heart Risk Oct 7, 2005 Clinical Data on FACTIVE(R) Tablets for ABS and AECB Presented at ... Oct 7, 2005 EFNS: Skin Patch Eases Early and Late Parkinson's Symptoms Sep 19, 2005 Locked Into Place Sep 11, 2005 Nurse leads mission to Haiti Sep 22, 2005 Cheap branded drugs soon available in Botika ng Bayan Sep 9, 2005 LAMINITIS: A HORSE'S WORST NIGHTMARE Sep 1, 2005 Erectile dysfunction Aug 31, 2005 Impotence-Erectile Dysfunction Aug 27, 2005 NEW YORK MEDICATION RULES TO CHANGE Aug 10, 2005 Allergy skin tests: Identify the sources of your sneezing Jul 11, 2005 Allergy skin tests: Identify the sources of your sneezing 11 Jul 2005 Erectile Drugs, Used With Care, Help Jun 28, 2005 LAMINITIS: A HORSE'S WORST NIGHTMARE Jun 28, 2005 Pharma firm’s ‘Value Health’ expands medicine discounts Jun 19, 2005 Oscient Pharmaceuticals Achieves Primary Endpoint in Phase III ... Jun 6, 2005 | ||
| Dosage Forms | Tablets; Oral solution | ||
| Drug_Category | Analgesics; Anti-ulcer Agents; Adjuvants; Histamine Antagonists; ATC:A02BA01 | ||
| Absorption | Rapid 60-70% | ||
| Interactions |
-->Interactions for Cimetidine: Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin, propranolol, nifedipine, chlordiazepoxide, diazepam, certain tricyclic antidepressants, lidocaine, theophylline and metronidazole, thereby delaying elimination and increasing blood levels of these drugs. Clinically significant effects have been reported with the warfarin anticoagulants; therefore, close monitoring of prothrombin time is recommended, and adjustment of the anticoagulant dose may be necessary when Tagamet is administered concomitantly. Interaction with phenytoin, lidocaine and theophylline has also been reported to produce adverse clinical effects. However, a crossover study in healthy subjects receiving either Tagamet 300 mg q.i.d. or 800 mg h.s. concomitantly with a 300 mg b.i.d. dosage of theophylline (Theo-Dur®, Key Pharmaceuticals, Inc.) demonstrated less alteration in steady-state theophylline peak serum levels with the 800 mg h.s. regimen, particularly in subjects aged 54 years and older. Data beyond 10 days are not available. (Note: All patients receiving theophylline should be monitored appropriately, regardless of concomitant drug therapy.) Dosage of the drugs mentioned above and other similarly metabolized drugs, particularly those of low therapeutic ratio or in patients with renal and/or hepatic impairment, may require adjustment when starting or stopping concomitantly administered Tagamet to maintain optimum therapeutic blood levels. Alteration of pH may affect absorption of certain drugs (e.g., ketoconazole). If these products are needed, they should be given at least 2 hours before cimetidine administration. Additional clinical experience may reveal other drugs affected by the concomitant administration of Tagamet. | ||
| Toxicity | nausea, vomiting, diarrhea, increased saliva production, difficulty breathing, and a fast heartbeat. | ||
| Organisms Affected | Humans and other mammals | ||
| Chemical IUPAC Name | 1-cyano-2-methyl-3-[2-[(5-methyl-1H-imidazol-4-yl)methylsulfanyl]ethyl]guanidine | ||
| Chemical Formula | C10H16N6S | ||
| Molecular Weight | 252.34 g/mol | ||
| Smiles String | CC1=C(N=CN1)CSCCNC(=NC)NC#N | ||
| Melting Point | 142 °C | ||
| Water Solubility | 0.5 g/100 mL | ||
| State | Solid | ||
| LogP/Hphobicity | 0.879 | ||
| Isoelectric Point | 6.8 | ||
| Biotransformation | Hepatic | ||
| Half Life | 2 hours | ||
| Protein Binding [%] | 15-20% | ||
| RxList Link | RXlist | ||
| Sponsored links | |||
| Drug Reference |
http://www.drugs.com/cons/Cimetidine.html http://www.rxlist.com/cgi/generic/cimet.htm | ||
| Drug Type | Approved Drug | ||
| Accession No | APRD00568 | ||
| CAS Registry Number | 51481-61-9 | ||
| KEGG Compound ID | C06952 | ||
| PubChem ID | SID:180968 | ||
| PharmGKB ID | PA449001 | ||
| SwissProt ID | Not Available | ||
| GenBank ID | Not Available | ||
| Drug ID Number [DIN] | 749494 |
|
Home | About | Cancers | Treatment | Medications Copyright onconews.org 2005. All Rights Reserved. |